Charleston

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Fibromyalgia2 trials
• High blood pressure2 trials
• Narcolepsy2 trials
• Pulmonary arterial hypertension2 trials
• Insomnia1 trial
• Migraine1 trial

Phase

• Phase 36 trials
• Phase 22 trials

Status

• Completed3 trials
• Recruiting3 trials
• Active, not recruiting1 trial
• Enrolling by invitation1 trial

Lead sponsor

• Axsome Therapeutics, Inc.6 trials
• Pulmovant, Inc.2 trials

Running trials

• Enrolling by invitation

  Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

  NCT07637162· Phase 3· Axsome Therapeutics, Inc.· Source

• Recruiting

  Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

  NCT07398417· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

• Recruiting

  A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

  NCT07333183· Phase 2· Pulmovant, Inc.· Source

  Contact: Clinical Site

• Active, not recruiting

  A Study of Mosliciguat in PH-ILD

  NCT06635850· Phase 2· Pulmovant, Inc.· Source

• Recruiting

  Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

  NCT06568367· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fibromyalgia2 recruiting
• High blood pressure1 recruiting
• Insomnia1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

  NCT05550207· Phase 3· Axsome Therapeutics, Inc.· Source

• Completed

  A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

  NCT05113745· Phase 3· Axsome Therapeutics, Inc.· Source

• Completed

  A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

  NCT05059223· Phase 3· Axsome Therapeutics, Inc.· Source